射血分数保留心力衰竭的脂肪因子假说:解释发病机制并指导治疗的新框架
本文提出一个统一假说:射血分数保留的心力衰竭(HFpEF)主要源于内脏脂肪扩张及功能失调转化,导致脂肪因子分泌谱改变,引起全身炎症、血浆容量扩张及心肌肥厚纤维化。框架将脂肪因子分为三个功能域,HFpEF由促炎促纤维化因子升高而保护性因子受抑的失衡所致,多条证据支持脂肪驱动机制。
要点
- HFpEF或由内脏脂肪功能失调驱动,而非异质性共病或心肌原发疾病。
- 脂肪因子分三域:保护性受抑、代偿性上调、促炎促纤维化抗钠尿。
- 中心性肥胖见于>95%的HFpEF患者,且与疾病严重程度相关。
核心结论
- HFpEF是脂肪驱动、通过内分泌-旁分泌信号播散至心脏的紊乱,而非异质性共病或心肌原发疾病。
研究设计与样本
- 本文为假说性论文,提出并整合脂肪因子假说框架,未报告原始研究样本量或系统检索方法。
主要发现
- 肥胖和膳食营养过剩是实验性HFpEF的主要驱动因素。
- 内脏脂肪和循环脂肪因子变化在社区人群诊断HFpEF(而非射血分数降低心衰)前数年即可观察到并预测诊断。
- 中心性肥胖或内脏脂肪存在于>95%的HFpEF患者中,并与疾病严重程度相关。
- 减重手术或HFpEF药物治疗可使内脏脂肪库缩小(与体重变化不成比例),同时增加域I脂肪因子、减少域III脂肪因子。
- 过度肥胖可能识别最可能对当前HFpEF治疗有反应的患者。
关键数值与推荐
- 域I脂肪因子为心脏保护性分子,在过度肥胖患者中受抑制。
- 域II脂肪因子为心脏保护性分子,在肥胖中作为代偿反应上调。
- 域III脂肪因子在肥胖中分泌增加,具有促炎、促肥厚、促纤维化和抗钠尿效应。
- 中心性肥胖或内脏脂肪存在于>95%的HFpEF患者中。
临床怎么用
- 评估HFpEF患者时应关注中心性肥胖和内脏脂肪,其与疾病严重程度相关。
- 过度肥胖可能有助于识别对当前HFpEF治疗更可能应答的患者。
- 针对脂肪组织减少域III脂肪因子并增加域I脂肪因子的干预是潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HYPOTHESIS: The paper proposes a novel unifying hypothesis-that heart failure with preserved ejection fraction (HFpEF) arises primarily from the expansion and dysfunctional transformation of visceral adipose tissue, leading to the secretion of altered suite of signaling molecules (adipokines), which causes systemic inflammation, plasma volume expansion, and cardiac hypertrophy and fibrosis. ELEMENTS OF THE FRAMEWORK: The framework groups adipokines into 3 domains. Domain I adipokines are cardioprotective molecules but are suppressed in patients with excess adiposity. Domain II adipokines are cardioprotective molecules that are up-regulated by adiposity as a compensatory response mechanism. Domain III adipokines, whose secretion is heightened in adiposity, have proinflammatory, prohypertrophic, profibrotic, and antinatriuretic effects. HFpEF results from an adiposity-driven imbalance that promotes Domain III adipokines but suppresses Domain I adipokines, with Domain II adipokines representing an inadequate counter-regulatory response. KEY LINES OF EVIDENCE: 1) Obesity and dietary nutrient excess are the major drivers of experimental HFpEF; 2) changes in visceral adiposity and circulating adipokines are observed years before and predict the diagnosis of HFpEF (but not heart failure with a reduced ejection fraction) in the general community; 3) central obesity or visceral adiposity is present in >95% of patients with HFpEF and tracks with disease severity; 4) obesity and HFpEF exhibit striking parallelism in their molecular, pathophysiological, and clinical features; 5) characteristic changes in the adipokine profile occur in parallel in central obesity and heart failure and are correlated with disease severity; 6) adipokines have established effects on cardiac structure and function that can lead to HFpEF; 7) bariatric surgery or drug treatments for HFpEF cause shrinkage of visceral fat depots (disproportionate to changes in body weight), while simultaneously increasing Domain I adipokines and decreasing Domain III adipokines; 8) excess adiposity appears to identify patients most likely to respond to current treatments for HFpEF; and 9) experimental interventions that target only adipose tissue to selectively increase or decrease its secretion of specific adipokines cause distant effects on the heart to modulate cardiac structure and the evolution of cardiomyopathy. CONCLUSIONS: The totality of evidence suggests that HFpEF evolves-not as a heterogenous disorder related to diverse comorbidities and not as a primary disorder of cardiomyocytes-but as an adipose-driven derangement that is disseminated (through endocrine-paracrine signaling) to the heart.
引用
- Packer. The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. J Am Coll Cardiol. 2025. PMID: 40886173. doi:10.1016/j.jacc.2025.06.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。